Frank P. McCormick
University of California, San Francisco
Cellular and Developmental Biology
Known for his research on the fundamental differences between normal cells and cancer cells that allow development of novel therapeutic strategies, in areas that include: p21-Ras and other oncogenes, p53 and other tumor suppressors, protein kinases, and neurofibromatosis. After an early research career in the biotechnology industry (1981-92), Frank founded and directed a successful biotech company (Onyx Pharmaceuticals; 1992-96), and then moved into academia as Director of the Helen Diller Family Comprehensive Cancer Center and Cancer Research Institute of the University of California, San Francisco (1997-present). In 2013 took the position as Scientific Director of the Leidos/Frederick National Laboratory for Cancer Research National Ras Program.